Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Sep 19, 2021

ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

*Phase 3 trial met its primary and key secondary endpoints
Sep 16, 2021

Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Sep 13, 2021

Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission

Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
Sep 9, 2021

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Aug 30, 2021

Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months

Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.